The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Abstract
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a pivotal role in mediating cell size and mass, proliferation, and survival. mTOR has also emerged as an important modulator of several forms of renal disease. mTOR is activated after acute kidney injury and contributes to renal regeneration and repair. Inhibition of mTOR with rapamycin delays recovery of renal function after acute kidney injury. Activation of mTOR within the kidney also occurs in animal models of diabetic nephropathy and other causes of progressive kidney disease. Rapamycin ameliorates several key mechanisms believed to mediate changes associated with the progressive loss of GFR in chronic kidney disease. These include glomerular hypertrophy, intrarenal inflammation, and interstitial fibrosis. mTOR also plays an important role in mediating cyst formation and enlargement in autosomal dominant polycystic kidney disease. Inhibition of mTOR by rapamycin or one of its analogues represents a potentially novel treatment for autosomal dominant polycystic kidney disease. Finally, inhibitors of mTOR improve survival in patients with metastatic renal cell carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lee, M., Hwang, J.-T., Lee, H.-J., Jung, S.-N., Kang, I., Chi, S.-G., Kim, S.-S., & Ha, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306104200 · Cited by 235
RetractedPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Growing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,560
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: Metabolic Sensors of the Eukaryotic Cell?
Hardie, D. G., Carling, D., & Carlson, M. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.821 · Cited by 1,435
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Pathophysiology of Progressive Nephropathies
Remuzzi, G., & Bertani, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392007 · Cited by 1,269
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
Liu, Y. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000106015.29070.e7 · Cited by 1,055
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s79 · Cited by 1,042
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Wilson, P. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022161 · Cited by 916
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., & Blenis, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.200-216.2004 · Cited by 868
Advances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
The Progression of Renal Disease
Epstein, F. H., Klahr, S., Schreiner, G., & Ichikawa, I. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806233182505 · Cited by 828
AMP-Activated Protein Kinase – Development of the Energy Sensor Concept
Hardie, D. G., Hawley, S. A., & Scott, J. W. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108944 · Cited by 813
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Sirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 757
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Witzgall, R., Brown, D., Schwarz, C., & Bonventre, J. V. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117214 · Cited by 603
Dedifferentiation and Proliferation of Surviving Epithelial Cells in Acute Renal Failure
Bonventre, J. V. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000067652.51441.21 · Cited by 593
Genetics and Pathogenesis of Polycystic Kidney Disease
Igarashi, P., & Somlo, S. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000028643.17901.42 · Cited by 593
Lamouille, S., & Derynck, R. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611146 · Cited by 572
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
Torres, V. E., Wang, X., Qian, Q., Somlo, S., Harris, P. C., & Gattone, V. H. (2004) · Nature Medicine · doi:10.1038/nm1004 · Cited by 482
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease
Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080660 · Cited by 391
Biological consequences of tumor hypoxia
HOCKEL, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90211-8 · Cited by 382
Fraenkel, M., Ketzinel-Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M.-F., Magnan, C., Cerasi, E., Kaiser, N., et al. (2008) · Diabetes · doi:10.2337/db07-0922 · Cited by 380
Restraining PI3K: mTOR signalling goes back to the membrane
Harrington, L. S., Findlay, G. M., & Lamb, R. F. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.003 · Cited by 366
Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J., & Proud, C. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414499200 · Cited by 355
Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., et al. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb09058.x · Cited by 345
Wang, X., Gattone, V., Harris, P. C., & Torres, V. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121090 · Cited by 334
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 317
Kenerson, H. L., Aicher, L. D., True, L. D., & Yeung, R. S. W. (2002) · PubMed · Cited by 315
BEUGNET, A., TEE, A. R., TAYLOR, P. M., & PROUD, C. G. (2003) · Biochemical Journal · doi:10.1042/bj20021266 · Cited by 307
Wolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 289
Wahl, P. R., Serra, A. L., Le Hir, M., Molle, K. D., Hall, M. N., & Wüthrich, R. P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi181 · Cited by 287
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
Lee, M.-J., Feliers, D., Mariappan, M. M., Sataranatarajan, K., Mahimainathan, L., Musi, N., Foretz, M., Viollet, B., Weinberg, J. M., Choudhury, G. G., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00278.2006 · Cited by 285
Flechner, S. M., Kurian, S. M., Solez, K., Cook, D. J., Burke, J. T., Rollin, H., Hammond, J. A., Whisenant, T., Lanigan, C. M., Head, S. R., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00627.x · Cited by 281
Lieberthal, W., Fuhro, R., Andry, C. C., Rennke, H., Abernathy, V. E., Koh, J. S., Valeri, R., & Levine, J. S. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.4.f693 · Cited by 270
Self-citationGingras, A.-C., Raught, B., & Sonenberg, N. (2004) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-18930-2_11 · Cited by 246
Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats
Lloberas, N., Cruzado, J. M., Franquesa, M., Herrero-Fresneda, I., Torras, J., Alperovich, G., Rama, I., Vidal, A., & Grinyó, J. M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050549 · Cited by 245
Molecular pathogenesis of ADPKD: The polycystin complex gets complex
Ong, A. C. M., & Harris, P. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00201.x · Cited by 242
Diekmann, F., Budde, K., Oppenheimer, F., Fritsche, L., Neumayer, H. H., & Campistol, J. M. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00590.x · Cited by 242
Tee, A. R., Anjum, R., & Blenis, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303257200 · Cited by 217
The von Hippel–Lindau tumor suppressor protein
Ivan, M., & Kaelin, W. G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00152-0 · Cited by 211
c-myc as an inducer of polycystic kidney disease in transgenic mice
Trudel, M., D'Agati, V., & Costantini, F. (1991) · Kidney International · doi:10.1038/ki.1991.80 · Cited by 210
Chronic Kidney Disease Progression
Eddy, A. A., & Neilson, E. G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070704 · Cited by 200
Abraham, R. T. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80172-6 · Cited by 192
Toward a Unified Theory of Renal Progression
Harris, R. C., & Neilson, E. G. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131342 · Cited by 192
Streit, F., Armstrong, V. W., & Oellerich, M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.6.955 · Cited by 191
Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma
Klatte, T., Seligson, D. B., Riggs, S. B., Leppert, J. T., Berkman, M. K., Kleid, M. D., Yu, H., Kabbinavar, F. F., Pantuck, A. J., & Belldegrun, A. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0411 · Cited by 181
mTOR pathway as a target in tissue hypertrophy
Lee, C.-H., Inoki, K., & Guan, K.-L. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105359 · Cited by 179
Navolanic, P., Steelman, L., & McCubrey, J. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.2.237 · Cited by 176
Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in Rats
Yang, Y., Wang, J., Qin, L., Shou, Z., Zhao, J., Wang, H., Chen, Y., & Chen, J. (2007) · American Journal of Nephrology · doi:10.1159/000106782 · Cited by 174
Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
McTaggart, R. A., Gottlieb, D., Brooks, J., Bacchetti, P., Roberts, J. P., Tomlanovich, S., & Feng, S. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00078.x · Cited by 170
Targeted therapy for metastatic renal cell carcinoma
Patel, P. H., Chaganti, R. S. K., & Motzer, R. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602978 · Cited by 169
Progression of Renal Disease and Renal Hypertrophy
Hostetter, T. H. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.001403 · Cited by 166
Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice
Sakaguchi, M., Isono, M., Isshiki, K., Sugimoto, T., Koya, D., & Kashiwagi, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.012 · Cited by 164
Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis
Wu, M.-J., Wen, M.-C., Chiu, Y.-T., Chiou, Y.-Y., Shu, K.-H., & Tang, M.-J. (2006) · Kidney International · doi:10.1038/sj.ki.5000161 · Cited by 164
Bonegio, R. G. B., Fuhro, R., Wang, Z., Valeri, C. R., Andry, C., Salant, D. J., & Lieberthal, W. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004030180 · Cited by 162
Self-citationThinking globally and acting locally with TOR
Arsham, A. M., & Neufeld, T. P. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.09.005 · Cited by 149
Delayed Graft Function and Cast Nephropathy Associated with Tacrolimus Plus Rapamycin Use
Smith, K. D., Wrenshall, L. E., Nicosia, R. F., Pichler, R. H., Marsh, C. L., Alpers, C. E., Polissar, N. L., & Davis, C. L. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000057542.86377.5a · Cited by 149
Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease.
Cowley, B. D., Smardo, F. L., Grantham, J. J., & Calvet, J. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8394 · Cited by 147
The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists
Thibonnier, M., Coles, P., Thibonnier, A., & Shoham, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.175 · Cited by 146
Shegogue, D., & Trojanowska, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401238200 · Cited by 134
Garcia, J. A., & Danielpour, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2408 · Cited by 131
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Costa, L. J., & Drabkin, H. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1404 · Cited by 127
Role of Mammalian Target of Rapamycin Signaling in Compensatory Renal Hypertrophy
Chen, J., Chen, J., Neilson, E. G., & Harris, R. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100894 · Cited by 126
Regulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy
Sataranatarajan, K., Mariappan, M. M., Lee, M. J., Féliers, D., Choudhury, G. G., Barnes, J. L., & Kasinath, B. S. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070412 · Cited by 125
Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology
Sutter, M., & Germino, G. G. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2003.13 · Cited by 124
Pon, Y. L., Zhou, H. Y., Cheung, A., Ngan, H., & Wong, A. S. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6302 · Cited by 122
Acute renal failure. III. The role of growth factors in the process of renal regeneration and repair
Nigám, S. K., & Lieberthal, W. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.279.1.f3 · Cited by 118
Self-citationJulian, B. A., & Novák, J. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200403000-00005 · Cited by 114
Dickson, L. M., Lingohr, M. K., McCuaig, J. F., Hügl, S., Snow, L., Kahn, B. B., Myers, M. G., & Rhodes, C. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101257200 · Cited by 110
Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies
Fervenza, F. C., Fitzpatrick, P. M., Mertz, J., Erickson, S. B., Liggett, S. B., Popham, S., Wochos, D. N., Synhavsky, A., Hippler, S. E., Larson, T. S., et al. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh079 · Cited by 110
AMP-activated protein kinase: the guardian of cardiac energy status
Hardie, D. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22683 · Cited by 105
Brenneisen, P., Wenk, J., Wlaschek, M., Krieg, T., & Scharffetter‐Kochanek, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4336 · Cited by 102
Recent advances in the regulation of the TOR pathway by insulin and nutrients
Avruch, J., Lin, Y., Long, X., Murthy, S., & Ortiz-Vega, S. (2004) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200501000-00010 · Cited by 101
Loverre, A., Ditonno, P., Crovace, A., Gesualdo, L., Ranieri, E., Pontrelli, P., Stallone, G., Infante, B., Schena, A., Paolo, S. D., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000139932.00971.e4 · Cited by 100
Chiu, T. T., Santiskulvong, C., & Rozengurt, E. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00200.2004 · Cited by 91
Koebnick, C., García, A. L., Dagnelie, P. C., Strassner, C., Lindemans, J. W., Katz, N. R., Leitzmann, C., & Hoffmann, I. (2005) · Journal of Nutrition · doi:10.1093/jn/135.10.2372 · Cited by 90
Schaefer, L., Tsalastra, W., Bábelová, A., Baliova, M., Minnerup, J., Sorokin, L. M., Gröne, H., Reinhardt, D. P., Pfeilschifter, J. M., Iozzo, R. V., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060497 · Cited by 88
Lieberthal, W. (1998) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199805000-00009 · Cited by 82
Self-citationMariappan, M. M., Féliers, D., Mummidi, S., Choudhury, G. G., & Kasinath, B. S. (2007) · Diabetes · doi:10.2337/db05-1334 · Cited by 79
Reiter, A. K., Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00333.2004 · Cited by 77
Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure
Megyesi, J. K., Andrade, L., Vieira, J. M., Safirstein, R. L., & Price, P. M. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00078.2002 · Cited by 75
Role of TSC–mTOR pathway in diabetic nephropathy
Inoki, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.028 · Cited by 73
Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity
Cho, M. E., Hurley, J. K., & Kopp, J. B. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.020 · Cited by 69
Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury
Fuller, T. F., Freise, C. E., Serkova, N. J., Niemann, C. U., Olson, J. L., & Feng, S. (2003) · Transplantation · doi:10.1097/01.tp.0000095897.38634.30 · Cited by 69
mRNA Translation: Unexplored Territory in Renal Science
Kasinath, B. S., Mariappan, M. M., Sataranatarajan, K., Lee, M. J., & Féliers, D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050488 · Cited by 69
Krämer, S., Wang-Rosenke, Y., Scholl, V., Binder, E., Loof, T., Khadzhynov, D., Kawachi, H., Shimizu, F., Diekmann, F., Budde, K., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00379.2007 · Cited by 66
Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse
Harding, M. A., Gattone, V. H., Grantham, J. J., & Calvet, J. P. (1992) · Kidney International · doi:10.1038/ki.1992.44 · Cited by 65
VEGF receptor inhibition slows the progression of polycystic kidney disease
Tao, Y., Kim, J., Yin, Y., Zafar, I., Falk, S. A., He, Z., Faubel, S. G., Schrier, R. W., & Edelstein, C. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002550 · Cited by 62
Canabal, D. D., Potian, J. G., Durán, R. G., McArdle, J. J., & Routh, V. H. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00207.2007 · Cited by 60
Lieberthal, W., Fuhro, R. L., Andry, C., Patel, V. A., & Levine, J. S. (2006) · Transplantation · doi:10.1097/01.tp.0000225772.22757.5e · Cited by 58
Self-citationMammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease
Edelstein, C. L. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05611207 · Cited by 57
Wang, Y., Krämer, S., Loof, T., Martini, S., Kron, S., Kawachi, H., Shimizu, F., Neumayer, H., & Peters, H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00380.x · Cited by 54
Diekmann, F., Rovira, J., Carreras, J., Arellano, E. M., Accent]n-Maneus, E. B. T. A., Ramírez-Bajo, M. J., Gutiérrez-Dalmau, Á., Brunet, M., & Campistol, J. M. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010087 · Cited by 54
Daniel, C., Ziswiler, R., Frey, B. M., Pfister, M., & Marti, H. (2000) · Nephron Experimental Nephrology · doi:10.1159/000020648 · Cited by 53
Mechanisms of Everolimus‐Induced Glomerulosclerosis After Glomerular Injury in the Rat
Daniel, C., Renders, L., Amann, K., Schulze-Lohoff, E., Hauser, I. A., & Hugo, C. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01120.x · Cited by 50
Polak, P., & Hall, M. N. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.09.005 · Cited by 50
Peters, H., Martini, S., Wang, Y., Shimizu, F., Kawachi, H., Krämer, S., & Neumayer, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00906.x · Cited by 47
Caspase-3 Gene Deletion Prolongs Survival in Polycystic Kidney Disease
Tao, Y., Zafar, I., Kim, J., Schrier, R. W., & Edelstein, C. L. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121378 · Cited by 44
Camardo, J. S. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00356-7 · Cited by 43
Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression.
Estacio, R. O., & Schrier, R. W. (2001) · PubMed · Cited by 42
Krämer, S., Loof, T., Martini, S., Rückert, M., Wang, Y., Böhler, T., Shimizu, F., Kawachi, H., Neumayer, H., & Peters, H. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00442.2004 · Cited by 40
The Role of Immunosuppressive Drugs in Aggravating Renal Ischemia and Reperfusion Injury
Gonçalves, G. M., Cenedeze, M. A., Feitoza, C. Q., de Paula, C. B., Marques, G. D. M., Pinheiro, H. S., Teixeira, V. D. P. A., dos Reis, M. A., Pacheco‐Silva, Á., & Câmara, N. O. S. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.01.027 · Cited by 34
Aguiari, G., Trimi, V., Bogo, M., Mangolini, A., Szabadkai, G., Pinton, P., Witzgall, R., Harris, P. C., Borea, P. A., Rizzuto, R., et al. (2008) · Cell Proliferation · doi:10.1111/j.1365-2184.2008.00529.x · Cited by 32
Rapamycin and chronic kidney disease: beyond the inhibition of inflammation
Liu, Y. (2006) · Kidney International · doi:10.1038/sj.ki.5001543 · Cited by 30
Emerging therapies for polycystic kidney disease
GATTONEII, V. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.016 · Cited by 24
Therapeutic interventions for autosomal dominant polycystic kidney disease.
Edelstein, C. L. (2008) · PubMed · Cited by 7
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease
Donato, A. J., Machin, D. R., & Lesniewski, L. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312563 · Cited by 688
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Metadata
- Authors
- Lieberthal, W., & Levine, J. S.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-12
- Volume
- 20
- Issue
- 12
- Pages
- 2493-2502
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2132123065
- Cited by
- 280
- References
- 133
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.